Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 1, 2007, Pages 87-94

  Havu Aurén, Katja ^a   Kiiski, Johanna ^a   Lehtiö, Kaisa ^a   Eskola, Olli ^a   Kulvik, Martti ^b   Vuorinen, Ville ^c   Oikonen, Vesa ^a   Vähätalo, Jyrki ^b   Jääskeläinen, Juha ^d   Minn, Heikki ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

18F FBPA; BNCT; NF2; PET

Indexed keywords

4 BORONO 2 FLUOROPHENYLALANINE F 18; BORON 10; TRACER;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CELL METABOLISM; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TUMOR LEVEL; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; NEUTRON CAPTURE THERAPY; POSITRON EMISSION TOMOGRAPHY; STANDARDIZATION;

ADULT; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEURILEMMOMA; NEUROFIBROMATOSES; PHENYLALANINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 33845358963     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0154-y     Document Type: Article

References (26)

1. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-1050
2. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-521
3. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800
4. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57
5. Louis DN, Stemmer-Rachamimov AO, Wiestler OD. Neurofibromatosis type 2. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 219-222
6. Louis DN, Scheithauer BW, Budka H. Meningeomas. In: Kleihues P, Cavanee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 176-184
7. Woodruff JM, Kourea HP, Louis DN. Schwannoma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 164-171
8. Subach BR, Kondziolka D, Lundsford LD, Bissonette DJ, Flickinger JC, Maitz AH. Stereotactic radiosurgery in the management of acoustic neurinomas associated with neurofibromatosis type 2. J Neurosurg 1999;90:815-822
9. Barth RF, Soloway AH, Goodman JH, Gahbauer RA, Gupta N, Blue TE, et al. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 1999;44:433-451
10. 10B compound. Lancet 1989;2:388-389
11. Kouri M, Kankaanranta L, Seppälä T, Tervo L, Rasilainen M, Minn H, et al. Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy. Radiother Oncol 2004;72:83-85
12. Pinelli T, Zonta A, Altieri S, et al. From the first idea to the application to the human liver. In: Sauerwein W, Moss R, Witting A, editors. Research and development in neutron capture therapy. Bologna: Monduzzi Editore; 2002; p. 1065-1072
13. Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, et al. Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neuro-Oncol 2003;62:123-134
14. Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998;39:325-333
15. Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high grade gliomas: part I. Clin Cancer Res 1998;4:1825-1832
16. Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high grade gliomas: part II, Clin Cancer Res 1998;4:1833-1841
17. Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med 1997;38:1762-1767
18. 18F]fluoro-L-phenylalanine. Melanoma Res 1992;2:171-179
19. Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24:677-683
20. 10F] fluorophenylalanine with relatively high-specific activity. J Labelled Cpd Radiopharm 2002;45:697-704
21. Kaisti KK, Långsjö JW, Aalto S, Oikonen V, Sipila H, Teras M, et al. Effects of seroflurane, propofol and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption and blood volume in humans. Anesthesiology 2003;99:603-613
22. Pelizzari CA, Chen GT, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration on CT, PET and/or MR images of the brain. J Comput Assist Tomogr 1989;13:20-26
23. Witting A, Sauerwein WA, Coderre JA. Mechanisms of transport of borono-phenylalanine through the cell membrane. Radiat Res 2000;153:173-180
24. Lusis E, Gutmann DH. Meningioma: an update. Curr Opin Neurol 2004;17(6):687-692
25. Jager PL, VaalburgW, Pruim J, de Vries EGE, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-445
26. Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neuro-Oncol 2004;70(3):349-357